Abstract
Although its mechanism of action is not fully understood, vortioxetine is an inhibitor of serotonin (5-hydroxytryptamine [5-HT]) reuptake and an agonist at 5-HT1A receptors; a partial agonist at 5-HT1B receptors; and an antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors. According to Takeda, it is the fi rst and only antidepressant that increases the availability of serotonin by this unique combination of pharmacodynamic activity. The contribution of each of these mechanisms of action to vortioxetine’s antidepressant effect has not been established; however, they may represent an improvement over other antidepressants currently on the market, said Takeda.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
